Acrivon Therapeutics, Inc.
ACRV
$1.48
-$0.16-9.76%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.43% | 6.92% | 28.27% | 33.66% | 36.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.53% | 55.79% | 38.13% | 22.75% | 111.69% |
| Operating Income | -18.53% | -55.79% | -38.13% | -22.75% | -111.69% |
| Income Before Tax | -18.59% | -55.13% | -35.10% | -29.24% | -115.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.59% | -55.13% | -35.10% | -29.24% | -115.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.59% | -55.13% | -35.10% | -29.24% | -115.61% |
| EBIT | -18.53% | -55.79% | -38.13% | -22.75% | -111.69% |
| EBITDA | -17.92% | -55.52% | -37.80% | -22.26% | -112.87% |
| EPS Basic | 30.73% | 10.11% | 17.84% | -25.42% | -7.08% |
| Normalized Basic EPS | 30.46% | 10.11% | 17.84% | -25.41% | -4.81% |
| EPS Diluted | 30.73% | 10.11% | 17.84% | -25.42% | -7.08% |
| Normalized Diluted EPS | 30.46% | 10.11% | 17.84% | -25.41% | -4.81% |
| Average Basic Shares Outstanding | 71.22% | 72.57% | 64.46% | 3.06% | 101.34% |
| Average Diluted Shares Outstanding | 71.22% | 72.57% | 64.46% | 3.06% | 101.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
